JP7261158B2 - 抗体構築物 - Google Patents

抗体構築物 Download PDF

Info

Publication number
JP7261158B2
JP7261158B2 JP2019520869A JP2019520869A JP7261158B2 JP 7261158 B2 JP7261158 B2 JP 7261158B2 JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019520869 A JP2019520869 A JP 2019520869A JP 7261158 B2 JP7261158 B2 JP 7261158B2
Authority
JP
Japan
Prior art keywords
domain
amino acid
acid sequence
sequence
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534277A5 (OSRAM
JP2019534277A (ja
Inventor
ルーカス ベイリー，
ブライアン グレーザー，
チューフェイ リー，
ローランド グリーン，
Original Assignee
インベンラ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベンラ， インコーポレイテッド filed Critical インベンラ， インコーポレイテッド
Publication of JP2019534277A publication Critical patent/JP2019534277A/ja
Publication of JP2019534277A5 publication Critical patent/JP2019534277A5/ja
Priority to JP2022162426A priority Critical patent/JP7591015B2/ja
Application granted granted Critical
Publication of JP7261158B2 publication Critical patent/JP7261158B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019520869A 2016-10-19 2017-10-18 抗体構築物 Active JP7261158B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022162426A JP7591015B2 (ja) 2016-10-19 2022-10-07 抗体構築物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662410054P 2016-10-19 2016-10-19
US62/410,054 2016-10-19
US201762549894P 2017-08-24 2017-08-24
US62/549,894 2017-08-24
US201762555498P 2017-09-07 2017-09-07
US62/555,498 2017-09-07
PCT/US2017/057268 WO2018075692A2 (en) 2016-10-19 2017-10-18 Antibody constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162426A Division JP7591015B2 (ja) 2016-10-19 2022-10-07 抗体構築物

Publications (3)

Publication Number Publication Date
JP2019534277A JP2019534277A (ja) 2019-11-28
JP2019534277A5 JP2019534277A5 (OSRAM) 2020-11-26
JP7261158B2 true JP7261158B2 (ja) 2023-04-19

Family

ID=60452719

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019520869A Active JP7261158B2 (ja) 2016-10-19 2017-10-18 抗体構築物
JP2022162426A Active JP7591015B2 (ja) 2016-10-19 2022-10-07 抗体構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022162426A Active JP7591015B2 (ja) 2016-10-19 2022-10-07 抗体構築物

Country Status (10)

Country Link
US (2) US20180118811A1 (OSRAM)
EP (1) EP3529269B1 (OSRAM)
JP (2) JP7261158B2 (OSRAM)
KR (3) KR102617264B1 (OSRAM)
CN (3) CN118359705A (OSRAM)
AU (1) AU2017345454B2 (OSRAM)
CA (1) CA3041254A1 (OSRAM)
IL (1) IL266143A (OSRAM)
MX (1) MX421186B (OSRAM)
WO (1) WO2018075692A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102689285B1 (ko) 2014-11-26 2024-07-31 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CA3041254A1 (en) * 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin
JP7603578B2 (ja) 2018-03-30 2024-12-20 メルス ナムローゼ フェンノートシャップ 多価抗体
EP3781204A4 (en) * 2018-04-17 2022-03-30 Invenra, Inc. BINDING MOLECULES
AU2019256431A1 (en) 2018-04-18 2020-11-05 Exelixis, Inc. Anti-ror antibody constructs
WO2020007368A1 (zh) * 2018-07-06 2020-01-09 北京天成新脉生物技术有限公司 低adcc/cdc功能性单抗及其制备方法与应用
US20220213225A1 (en) * 2018-07-30 2022-07-07 Invenra Inc. Multispecific treg binding molecules
CN112996809A (zh) * 2018-10-10 2021-06-18 酵活有限公司 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
KR20210108421A (ko) 2018-12-24 2021-09-02 사노피 돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
CA3171363A1 (en) * 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same
JP2023515807A (ja) * 2020-02-20 2023-04-14 ウィン セラピューティクス， インコーポレイテッド 二重特異性のｇｄ２およびｂ７ｈ２結合分子ならびに使用方法
CA3207821A1 (en) * 2020-12-10 2022-06-16 Invenra Inc. Orthogonal mutations for heterodimerization
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
TW202506726A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 雙特異性工程化抗體
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515275A (ja) 2012-04-20 2015-05-28 メルス・ベー・フェー Ｉｇ様分子の生産方法および生産手段
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
US20150315296A1 (en) 2014-04-02 2015-11-05 Hoffmann-La Roche Inc. Multispecific antibodies
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905551D0 (en) * 1989-03-10 1989-04-19 Unilever Plc Detergent compositions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
EP2335725B1 (en) 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
CA2621502A1 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
NZ585547A (en) 2007-11-28 2012-12-21 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
RU2473360C2 (ru) 2007-11-30 2013-01-27 Эббот Лэборетриз Белковые композиции и способы их получения
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
PA8853201A1 (es) 2008-12-10 2010-07-27 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables
US8524214B2 (en) 2009-05-28 2013-09-03 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
WO2010141566A1 (en) 2009-06-03 2010-12-09 Immunogen, Inc. Conjugation methods
EP3216462A3 (en) 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
HRP20161753T1 (hr) 2010-11-11 2017-02-10 Abbvie Biotechnology Ltd Tekuće formulacije protutijela anti-tnf-alfa s visokom koncentracijom
MX355060B (es) * 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
JP5830085B2 (ja) 2011-03-10 2015-12-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｏａｔｐ１ｂ１の輸送活性を促進又は阻害する化合物をスクリーニングするための方法、及びｏａｔｐ１ｂ１発現量を測定するための方法
RU2617402C2 (ru) 2011-06-10 2017-04-25 Мерсана Терапьютикс, Инк. Конъюгаты белок-полимер-лекарственное средство
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
NZ741211A (en) 2012-05-15 2019-09-27 Seattle Genetics Inc Self-stabilizing linker conjugates
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
KR20150070384A (ko) 2012-10-25 2015-06-24 메디뮨 엘엘씨 안정한 저점도 항체 제제
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
WO2014160360A1 (en) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Tubulysin compounds and conjugates thereof
CA2926586C (en) 2013-10-11 2020-04-07 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
KR102538993B1 (ko) 2013-10-15 2023-06-02 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
MX385651B (es) 2013-12-19 2025-03-18 Seagen Inc Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.
EP3912641B1 (en) 2014-02-17 2024-11-06 Seagen Inc. Hydrophilic drug-linker compounds
JP2017512814A (ja) 2014-04-07 2017-05-25 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤
WO2015195925A1 (en) 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI551060B (zh) * 2014-09-24 2016-09-21 衡宇科技股份有限公司 Ｂｃｈ解碼方法及其解碼器
WO2016180941A1 (en) 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
SI3325482T1 (sl) 2015-07-21 2020-11-30 Immunogen, Inc. Postopki za pripravo citotoksičnih benzodiazepinskih derivatov
MA47022A (fr) 2016-02-05 2018-12-12 Immunogen Inc Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
CA3016474A1 (en) 2016-03-15 2017-09-21 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
EP3241531A1 (en) * 2016-05-04 2017-11-08 noonee AG Leg unit for a wearable sitting posture assisting device
CA3041254A1 (en) * 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
EP3781204A4 (en) * 2018-04-17 2022-03-30 Invenra, Inc. BINDING MOLECULES
CA3097605A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Trivalent trispecific antibody constructs
AU2019256431A1 (en) * 2018-04-18 2020-11-05 Exelixis, Inc. Anti-ror antibody constructs
US20220213225A1 (en) * 2018-07-30 2022-07-07 Invenra Inc. Multispecific treg binding molecules
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
JP2015515275A (ja) 2012-04-20 2015-05-28 メルス・ベー・フェー Ｉｇ様分子の生産方法および生産手段
US20150315296A1 (en) 2014-04-02 2015-11-05 Hoffmann-La Roche Inc. Multispecific antibodies
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody

Also Published As

Publication number Publication date
CN110177805A (zh) 2019-08-27
KR20240000650A (ko) 2024-01-02
KR20190092380A (ko) 2019-08-07
AU2017345454B2 (en) 2024-10-31
JP2019534277A (ja) 2019-11-28
MX421186B (es) 2025-02-10
AU2017345454A1 (en) 2019-05-30
EP3529269B1 (en) 2025-11-26
US20240043502A1 (en) 2024-02-08
KR102617264B1 (ko) 2023-12-29
CN118359704A (zh) 2024-07-19
WO2018075692A2 (en) 2018-04-26
CN118359705A (zh) 2024-07-19
EP3529269A2 (en) 2019-08-28
IL266143A (en) 2019-06-30
CA3041254A1 (en) 2018-04-26
US20180118811A1 (en) 2018-05-03
NZ752832A (en) 2025-06-27
JP2022176374A (ja) 2022-11-25
CN110177805B (zh) 2024-04-02
JP7591015B2 (ja) 2024-11-27
MX2019004690A (es) 2019-09-27
KR20250044934A (ko) 2025-04-01
WO2018075692A3 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
JP7591015B2 (ja) 抗体構築物
US20240392002A1 (en) Anti-ror antibody constructs
US20250026861A1 (en) Trivalent trispecific antibody constructs
US20210163594A1 (en) Binding molecules
US20220213225A1 (en) Multispecific treg binding molecules
US20220153844A1 (en) Multispecific treg binding molecules
WO2019183406A1 (en) Multispecific antibody purification with ch1 resin
EA048615B1 (ru) Конструкции антител к ror

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221007

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230117

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230407

R150 Certificate of patent or registration of utility model

Ref document number: 7261158

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150